SCHEMBL30330157

SCHEMBL30330157

CNc1cc(C)nc(Nc2cc3c(c(C4=CCN(C(=O)OC(C)(C)C)CCC4)c2)OCO3)c1

nearest known ligand 0.39

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ JAK1 P23458 1/20 0.39
▸ EHMT2 Q96KQ7 5/20 0.36
▸ EHMT1 Q9H9B1 5/20 0.36
▸ CCNT1 O60563 1/20 0.35
▸ CDK9 P50750 1/20 0.35
▸ PDK4 Q16654 1/20 0.35
▸ PDE10A Q9Y233 1/20 0.34
▸ MAPT P10636 3/20 0.33
▸ POLB P06746 2/20 0.33
▸ NAMPT P43490 1/20 0.33
▸ WNT3A P56704 1/20 0.33
▸ CYP11B2 P19099 1/20 0.33
▸ LMNA P02545 1/20 0.32
▸ TP53 P04637 1/20 0.32
▸ CNR1 P21554 1/20 0.32
▸ GRM5 P41594 1/20 0.32
▸ GRM1 Q13255 1/20 0.32
▸ GABRP O00591 1/20 0.32
▸ GABRD O14764 1/20 0.32
▸ GABRA1 P14867 1/20 0.32

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL30329643 1.00 JAK1 (0.39) JAK1EHMT2EHMT1CCNT1CDK9
SCHEMBL25166453 1.00 JAK1 (0.39) JAK1EHMT2EHMT1CCNT1CDK9
SCHEMBL31108063 0.94 JAK1 (0.38) JAK1EHMT2EHMT1CCNT1CDK9
SCHEMBL25165936 0.94 JAK1 (0.38) JAK1EHMT2EHMT1CCNT1CDK9
SCHEMBL25166430 0.89 EHMT2 (0.47) JAK1EHMT2EHMT1
SCHEMBL30329712 0.89 EHMT2 (0.47) JAK1EHMT2EHMT1
SCHEMBL31168415 0.84 JAK1 (0.40) JAK1EHMT2EHMT1CCNT1CDK9
SCHEMBL25166290 0.83 EHMT2 (0.47) JAK1EHMT2EHMT1
SCHEMBL31108036 0.83 EHMT2 (0.47) JAK1EHMT2EHMT1
SCHEMBL30330245 0.83 EHMT2 (0.47) JAK1EHMT2EHMT1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20240368139-A1 NOVEL MODULATORS OF EHMT1 AND EHMT2 AND THERAPEUTIC USE THEREOF TANGO THERAPEUTICS, INC. 2024-11-07 — — US disclosed
EP-4416143-A1 NOVEL MODULATORS OF EHMT1 AND EHMT2 AND THERAPEUTIC USE THEREOF Tango Therapeutics, Inc. (US) 2024-08-21 — — EP disclosed
WO-2023064586-A1 NOVEL MODULATORS OF EHMT1 AND EHMT2 AND THERAPEUTIC USE THEREOF TANGO THERAPEUTICS, INC. (US) 2023-04-20 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20240368139-A1 NOVEL MODULATORS OF EHMT1 AND EHMT2 AND THERAPEUTIC USE THEREOF EHMT1, EHMT2, SHMT1 JAK1 3335/4885EHMT2 2/4885EHMT1 1/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback